Oral STAT6 Degrader BCR-0008 Clears China Clinical Entry

Company Hangzhou Baicreat Event Type Regulatory Clinical Clearance (NMPA CDE) Modality Oral PROTAC (Targeted Protein Degrader) Asset BCR-0008 Target STAT6 Disease Area Atopic Dermatitis and Asthma (Type 2 Inflammatory Disease) Summary Hangzhou Baicreat reported that China’s NMPA Center for Drug Evaluation permitted clinical testing of…